Hubei Jumpcan Pharmaceutical Co (SHSE:600566) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Hubei Jumpcan Pharmaceutical Co EBITDA Margin % Related Terms
Hubei Jumpcan Pharmaceutical Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hubei Jumpcan Pharmaceutical Co EBITDA Margin % Chart
SHSE:600566 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hubei Jumpcan Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hubei Jumpcan Pharmaceutical Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hubei Jumpcan Pharmaceutical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Hubei Jumpcan Pharmaceutical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hubei Jumpcan Pharmaceutical Co (SHSE:600566) has a EBITDA Margin % of 39.78% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hubei Jumpcan Pharmaceutical Co and its competitors. This is 30% above median its historical median of 30.70. Over the past decade, Hubei Jumpcan Pharmaceutical Co's EBITDA Margin % has ranged from 25.77 to 41.33. According to the industry distribution chart, Hubei Jumpcan Pharmaceutical Co ranks #81 out of 952 companies in the Drug Manufacturers industry, placing it in the top 8.5%.
Is Hubei Jumpcan Pharmaceutical Co's EBITDA Margin % too high?
Hubei Jumpcan Pharmaceutical Co's current EBITDA Margin % of 39.78% is 30% above median its 10-year median of 30.70. Over the past 10 years, this metric has ranged from a low of 25.77 to a high of 41.33. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Hubei Jumpcan Pharmaceutical Co's value of 39.78% is 219% above this industry median. Based on the distribution chart, Hubei Jumpcan Pharmaceutical Co ranks #81 out of 952 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hubei Jumpcan Pharmaceutical Co has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hubei Jumpcan Pharmaceutical Co's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hubei Jumpcan Pharmaceutical Co ranks #81 out of 952 companies for EBITDA Margin %. This places Hubei Jumpcan Pharmaceutical Co in the top 9% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.47. Hubei Jumpcan Pharmaceutical Co's value of 39.78% is 219% above this benchmark. Historically, Hubei Jumpcan Pharmaceutical Co's own EBITDA Margin % has ranged from 25.77 to 41.33 over the past decade. While the company's 10-year median is 30.70 vs. the industry median of 12.47, Hubei Jumpcan Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hubei Jumpcan Pharmaceutical Co's current EBITDA Margin % of 39.78% is 219% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hubei Jumpcan Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hubei Jumpcan Pharmaceutical Co's current EBITDA Margin % is 39.78%, which is 30% above median its own 10-year median of 30.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hubei Jumpcan Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Hubei Jumpcan Pharmaceutical Co (SHSE:600566) is currently considered Fairly Valued. The stock's GF Value™ is ¥20.89, compared to a current price of ¥21.88 — trading 4.7% above its estimated fair value. The current EBITDA Margin % is 39.78%, which is 30% above median its 10-year median of 30.70 and 219% above the Drug Manufacturers industry median of 12.47. Hubei Jumpcan Pharmaceutical Co's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Hubei Jumpcan Pharmaceutical Co (SHSE:600566), the current EBITDA Margin % is 39.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hubei Jumpcan Pharmaceutical Co (SHSE:600566) Overvalued in 2026?
Based on GuruFocus' analysis, Hubei Jumpcan Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥21.88 is trading 4.7% above its estimated GF Value™ of ¥20.89.
GuruFocus considers Hubei Jumpcan Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:600566:
EBITDA Margin %: 39.78% (30% above median its 10-year median of 30.70)
GF Value™: ¥20.89 vs. price of ¥21.88 (4.7% above fair value)
Industry Position: 219% above the Drug Manufacturers median (#81 of 952)
No single metric tells the full story. See the SHSE:600566 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hubei Jumpcan Pharmaceutical Co Business Description
Hubei Jumpcan Pharmaceutical Co Ltd engages in the research, development, manufacturing, and trading of Chinese traditional medicines, western medicines, daily use chemicals based on Chinese traditional medicines, and Chinese medicine health products in China. It offers Chinese and Western medicines in the areas of pediatrics, gynecology, pneumonology, gastroenterology, and geriatrics. The company also develops Chinese and Western medicines in the areas of detoxification, digestive system, respiratory system, nervous system, anti-infection, cardiovascular, narcotic analgesic, nutrition, musculoskeletal, and hemostasis.
86GF Score
Get the complete analysis for SHSE:600566
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600566 has been successfully added to your 
